Hemophilia A gene therapy: current and next-generation approaches
…, G Gonen-Yaacovi, OG Segurado - Expert Opinion on …, 2022 - Taylor & Francis
… G Gonen-Yaacovi and OG Segurado are employees of ASC Therapeutics, a biopharmaceutical
company headquartered in Milpitas, CA, USA. The funders had no role in the design of …
company headquartered in Milpitas, CA, USA. The funders had no role in the design of …
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
…, AF Kavanaugh, EK Chartash, OG Segurado - Annals of the …, 2006 - ard.bmj.com
Objective: To evaluate the efficacy and safety of adalimumab plus methotrexate (MTX) given
for up to 4 years in patients with active, longstanding rheumatoid arthritis. Methods: Patients …
for up to 4 years in patients with active, longstanding rheumatoid arthritis. Methods: Patients …
HUMIRA® Pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab
A Kivitz, OG Segurado - Expert Review of Medical Devices, 2007 - Taylor & Francis
… Oscar Segurado, along with another investigator, was responsible for the planning and
design of the study, as well as analysis and interpretation of the data. Segurado is an employee …
design of the study, as well as analysis and interpretation of the data. Segurado is an employee …
Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal …
…, S Thakker, FR Wellborne, CL Renz, OG Segurado - Clinical …, 2006 - Elsevier
BACKGROUND:: Adalimumab is a therapeutic monoclonal antibody for SC administration
by 2 single-use injection devices providing bioequivalent amounts of adalimumab: a ready-to-…
by 2 single-use injection devices providing bioequivalent amounts of adalimumab: a ready-to-…
Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
…, A Hofstetter, G Riethmüller, OG Segurado - … (Baltimore, Md.: 1950 …, 1993 - journals.aai.org
Metastatic renal cell carcinoma (RCC), like melanoma, belongs to the small group of human
tumors in which partial or complete remission has been observed in some patients after …
tumors in which partial or complete remission has been observed in some patients after …
Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count
T Pincus, OG Segurado - Annals of the Rheumatic Diseases, 2006 - ard.bmj.com
Objective: To ask rheumatologists about the likelihood of performing a formal joint count at
each visit of a patient with rheumatoid arthritis (RA) in standard clinical care. Method: Direct …
each visit of a patient with rheumatoid arthritis (RA) in standard clinical care. Method: Direct …
[PDF][PDF] Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis
OG Segurado, EH Sasso - Clin Exp Rheumatol, 2014 - academia.edu
Quantitative and regular assessment of disease activity in rheumatoid arthritis (RA) is
required to achieve treatment targets such as remission and to optimise clinical outcomes. To …
required to achieve treatment targets such as remission and to optimise clinical outcomes. To …
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab …
T Pincus, I Amara, OG Segurado, M Bergman… - The Journal of …, 2008 - jrheum.org
… Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most
rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2. …
rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2. …
An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid …
… Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most
rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2. …
rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2. …
Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis
A Davies, MA Cifaldi, OG Segurado… - The Journal of …, 2009 - jrheum.org
… Cifaldi and Segurado are employed by Abbott, and, at the time of the analysis, Mr. Davies
was employed by United BioSource, contracted by Abbott to perform this analysis. …
was employed by United BioSource, contracted by Abbott to perform this analysis. …